Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a Double Blind, Randomized, Parallel Arm, Placebo-controlled Trial to Investigate the Effects of Two Dose Levels of CIT-013 on Disease Activity in Patients With Moderate to Severe Rheumatoid Arthritis (RA)

Next Previous
Trial Profile

A Phase 2a Double Blind, Randomized, Parallel Arm, Placebo-controlled Trial to Investigate the Effects of Two Dose Levels of CIT-013 on Disease Activity in Patients With Moderate to Severe Rheumatoid Arthritis (RA)

Status: Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Aug 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CIT 013 (Primary)
  • Indications Rheumatoid arthritis
  • Focus Proof of concept; Therapeutic Use

Most Recent Events

  • 13 Aug 2025 Last checked against ClinicalTrials.gov record.
  • 30 Jul 2025 Planned number of patients changed from 150 to 88.
  • 20 Jul 2025 Planned initiation date changed from 1 Nov 2024 to 1 Aug 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top